Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.

제품 설명 

Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade

제품 번호

PX-TA1297

제품 특징

Description of Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade

General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody

Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.

QC & Validation Data

SDS-PAGE for Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb binds to CD158a / KIR2DL1, C-His, recombinant protein in indirect ELISA Assay

Immobilized CD158a / KIR2DL1, C-His, recombinant protein (cat. No.PX-P5573) at 0.5µg/mL (100µL/well) can bind to Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb (cat. No.PX-TA1297) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Publications

• Furkan Yigitbilek, Elif Ozdogan, Nitin Abrol, Walter D. Park, Michael J. Hansen, Surendra Dasari, Mark D. Stegall and Timucin Taner,Liver mesenchymal stem cells are superior inhibitors of NK cell functions through differences in their secretome compared to other mesenchymal stem cells,Front. Immunol., 21 September 2022, Sec. Alloimmunity and Transplantation, https://doi.org/10.3389/fimmu.2022.952262

ProteoGenix의 모든 제품들을 만나보세요!

• Proteins
• 
  
• Primary antibodies
• 
  
• Secondary antibodies
• 
  
• ELISA assay kits
• 
  
• Cell separation media
• 
  
• Other products

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"